The FDA's recent approval of Novavax's COVID-19 vaccine signifies the introduction of the first protein-based vaccine available in the U.S., targeting a narrower demographic than expected. Unlike Pfizer and Moderna, which are mRNA-based, this vaccine aims at adults aged 65 and older, or those between 12 to 64 with specific health conditions. This approval comes amidst broader changes at the FDA regarding vaccine policies, raising concerns about the availability of boosters in the upcoming seasons and whether these new guidelines will impact public health outcomes.
Novavax received FDA approval as the first protein-based COVID-19 vaccine in the U.S., targeting a more limited group than its mRNA counterparts, raising concerns about future booster availability.
The FDA's shift in vaccine approval procedures leads to uncertainty surrounding upcoming COVID-19 vaccinations, particularly in light of Novavax's recent authorization which comes with significant restrictions.
Collection
[
|
...
]